$HRMY

Harmony Biosciences (HRMY) told investors at Piper Sandler’s Virtual CNS Symposium that WAKIX continues to deliver record quarterly sales and funds its CNS pipeline. The company outlined pitolisant GR (PDUFA Apr 27) and pitolisant HD (top-line 2027, PDUFA 2028), plus BP-205 and EPX-100. HRMY shares closed at $38.5.

Harmony Biosciences (HRMY) reported Q2 2026 WAKIX net revenue of $261.3 million, up 30% year over year, and confirmed 2026 revenue guidance of $1.0 billion to $1.04 billion. Net income was $75.4 million ($1.28/diluted share). Cash and investments were $962.5 million as of June 30, 2026. The company also discussed BP-205 clinical data and pipeline timelines.

Harmony Biosciences (NASDAQ:HRMY) reported Q2 EPS of $1.28, above a 94-cent consensus, and sales of $261.3 million versus $248.41 million expected. WAKIX net revenue rose 30% to $261.3 million, and HRMY reiterated full-year WAKIX guidance of $1.0B to $1.04B. The company also shared Phase 1 BP-205 SAD data and plans Phase 2 studies from mid-2027.

Oppenheimer cut its Harmony Biosciences (NASDAQ:HRMY) price target to $70 from $85 but kept an Outperform rating after model updates. Harmony reported Q2 2026 Wakix net sales of $261.3M (+30% YoY) and reaffirmed full-year guidance of $1.00B to $1.04B. Oppenheimer cited new Phase 1 data for BP-205 and expects further Phase 1 readouts in Q4 2026 and early 2027.

Harmony Biosciences Holdings, Inc. (HRMY) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 hrmy-20260804xex99d1.htm EX-99.1 ‌ Exhibit 99.1 Harmony Biosciences Announces Record Q2 2026 Re venue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile WAKIX® Net Revenue Grew 30% Year over Year to $261.3 Millio

Harmony Biosciences Holdings, Inc. (HRMY) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-10.1 2 hrmy-20260716xex10d1.htm EX-10.1 ​ ​ ​ Exhibit 10.1 SEPARATION AGREEMENT This Separation Agreement (this “ Agreement ”) is entered into by and between Glenn Reicin (“ Executive ”) and Harmony Biosciences Holdings, Inc. and Harmony Biosciences Management, Inc. (together

Harmony Biosciences (NASDAQ: HRMY) is a commercial-stage pharma focused on rare neurological diseases, with WAKIX (pitolisant) as its FDA-approved treatment for narcolepsy-related excessive daytime sleepiness and cataplexy. The company reported Q1 2026 total revenue of $215.4 million (+17% YoY) and reaffirmed 2026 net revenue guidance of over $1 billion, citing ongoing WAKIX adoption.

The article says the US economy faces decelerating growth and persistent inflation risks, citing revised Q1 2026 GDP growth of 1.6% (down from 2%) and April 2026 PCE inflation of 3.8% (core 3.3%), per Reuters/BEA. It also lists “10 best stocks” chosen via AI and hedge-fund sentiment data; one example is Harmony Biosciences (HRMY), with Q1 2026 revenue of $215.4M (+17%) and 2026 net revenue guidance above $1B.

Harmony Biosciences Holdings, Inc. (HRMY) is highlighted as a top small-cap value stock, with analysts reiterating Buy ratings and raising price targets due to positive discussions and a strong patent portfolio for its drug WAKIX. The company is actively developing new pitolisant formulations and accelerating research into Clemizole Hydrochloride for rare neurological diseases. While acknowledging HRMY's potential, the article also promotes a separate "cheapest AI stock" with significant upside.

Harmony Biosciences is facing scrutiny over its pipeline following the 2025 acquisition of Epygenix Therapeutics, as Polaryx Therapeutics' recent 10-K filing reveals overlapping rare disease programs with their shared backer, Mstone Partners. US investors are closely monitoring how Harmony navigates integration challenges, competitive pressures, and the need to differentiate its assets in the neurology orphan drug market. The article highlights the strategic implications of these connections for Harmony's stock performance and resource allocation.